Results 201 to 210 of about 9,826,714 (353)

Cotargeting TREM2 and IL2 pathways triggers multipronged anticancer immunity

Molecular Oncology, EarlyView.
Von Locquenghien et al. report that MiTE‐144, a triggering receptor expressed on myeloid cells 2 (TREM2) blocking antibody fused to interleukin‐2 (IL2) variant with tumour microenvironment restricted activation, demonstrates superior anticancer efficiency in a preclinical setting.
Isaure Vanmeerbeek, Jenny Sprooten, Abhishek D. Garg   +2 more
wiley   +1 more source

Drug Delivery System for the Anticancer Drug Paclitaxel Using Lipocalin-Type Prostaglandin D Synthase Conjugated to a Tumor-Targeting Peptide. [PDF]

ACS Omega
Furuta K, Nakatsuji M, Yoshida H, Okubo R, Nishide K, Yamamura T, Inui T.   +6 more
europepmc   +1 more source

Colorectal cancer‐derived FGF19 is a metabolically active serum biomarker that exerts enteroendocrine effects on mouse liver

Molecular Oncology, EarlyView.
Meta‐transcriptome analysis identified FGF19 as a peptide enteroendocrine hormone associated with colorectal cancer prognosis. In vivo xenograft models showed release of FGF19 into the blood at levels that correlated with tumor volumes. Tumoral‐FGF19 altered murine liver metabolism through FGFR4, thereby reducing bile acid synthesis and increasing ...
Jordan M. Beardsley, Michael W. Rohr, Joseph A. Goode, Sai Preethi Nakkina, Jignesh G. Parikh, Deborah A. Altomare   +5 more
wiley   +1 more source

A bispecific antibody targeting PD-L1/TNFR2 increases tumor targeting and enhances antitumor efficacy in colorectal cancer. [PDF]

J Immunother Cancer
Kang X, Qian P, Han Y, Wu M, Li Y, Xu C, Wei J.   +6 more
europepmc   +1 more source

Molecular targeting: targeting angiogenesis in solid tumors

Annals of Oncology, 2004
J-C, Soria, J, Fayette, J-P, Armand
openaire   +2 more sources

Identification of serum protein biomarkers for pre‐cancerous lesions associated with pancreatic ductal adenocarcinoma

Molecular Oncology, EarlyView.
This work identified serum proteins associated with pancreatic epithelial neoplasms (PanINs) and early‐stage PDAC. Proteomics screens assessed genetically engineered mice with abundant PanINs, KPC mice (Lox‐STOP‐Lox‐KrasG12D/+ Lox‐STOP‐Lox‐Trp53R172H/+ Pdx1‐Cre) before PDAC development and also early‐stage PDAC patients (n = 31), compared to benign ...
Hannah Mearns, Jaclyn S. Long, Sergio Lilla, Kelly Hodge, Marcus J. G. W. Ladds, Colin Nixon, Paula Fernández‐Palanca, Sara Zanivan, Pilar Acedo, Stephen P. Pereira, Kevin M. Ryan   +10 more
wiley   +1 more source

Author Correction: Fusions of Tumor-derived Endothelial Cells with Dendritic Cells Induces Antitumor Immunity

Scientific Reports
Yingying Huang, Qiqi Mao, Jian He, Jing Su, Yi Peng, Wei Liang, Zixi Hu, Sufang Zhou, Xiaoling Lu, Yongxiang Zhao   +9 more
doaj   +1 more source

Ginsenoside Rh2- functionalized liposomes enhanced BRD4-PROTAC delivery and antitumor efficacy <i>via</i> improved tumor targeting and ECM remodeling. [PDF]

Mater Today Bio
Wen L, Rao J, Chen J, Li F, Chen X, Guo S, Cui B, Qiu C, Chen W.   +8 more
europepmc   +1 more source

Subtype‐specific enhancer RNAs define transcriptional regulators and prognosis in breast cancers

Molecular Oncology, EarlyView.
This study employed machine learning methodologies to perform the subtype‐specific classification of RNA‐seq data sets, which are mapped on enhancers from TCGA‐derived breast cancer patients. Their integration with gene expression (referred to as ProxCReAM eRNAs) and chromatin accessibility profiles has the potential to identify lineage‐specific and ...
Aamena Y. Patel, Peyman Zarrineh, Nathnael T. Tuffa, Jigar H. Sheth, Sumitra Mohan, Mudassar Iqbal, Sankari Nagarajan   +6 more
wiley   +1 more source

Integration of MicroRNAs with nanomedicine: tumor targeting and therapeutic approaches. [PDF]

Front Cell Dev Biol
Telkoparan-Akillilar P, Chichiarelli S, Tucci P, Saso L.   +3 more
europepmc   +1 more source